IONIQ Sciences visual overview
Salt Lake City, UT, February 2, 2023 – We’re delighted to unveil this visual overview of the modernization of early-stage cancer detection.
IONIQ measures the body’s immune response to the presence of cancer in its earliest, most-treatable stages. And we’re doing it with no needles, no radiation, and no surgery.
To support our planned Multi-Cancer Screen, our pipeline currently consists of three active components:
- An FDA-designated breakthrough device for lung cancer.
- A breast test already in feasibility trials and showing promising results.
- Gastrointestinal (GI) cancer tests supported by preliminary evidence.
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, please visit: www.biohive.com.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103